China IVF 2026 New Policy Interpretation: Scope, Reimbursement Conditions, and Process Changes

AI Summary

Main text begins

1. 2026 New IVF Policy: What Exactly Has Changed

Starting from January 2026, the National Health Commission, in conjunction with the National Healthcare Security Administration, officially implemented the second phase adjustment plan of the "Human Assisted Reproductive Technology Application Plan (2026-2030)". This adjustment is not a small-scale patch but a systematic restructuring of the coverage, access conditions, payment methods, and quality supervision of assisted reproduction.

1.1 Medical Insurance Reimbursement: From "Partial Pilots" to "National Unification"

Between 2024 and 2025, over 20 provinces had included assisted reproduction in their medical insurance, but reimbursement rates, caps, and covered items varied significantly. The core of the 2026 new policy is to establish a unified national medical insurance payment directory for assisted reproduction, ending province-by-province fragmentation.

• Increased Reimbursable Items: On top of the original "examination + egg retrieval + transfer", newly added are ovulation induction drugs (including recombinant FSH), embryo freezing (first year), and PGT-A/PGT-M testing (limited to indicated populations).
• Reimbursement Rate: 70% for urban employee medical insurance, 50% for urban and rural resident medical insurance, with a unified annual cap of 35,000 RMB per person.
• Not Covered: Assisted embryo hatching, surcharges for intracytoplasmic sperm injection (ICSI), non-medical sex selection, and third-party assisted reproduction.

1.2 Indication Adjustments: Who Can Do It

The 2026 new policy has moderately relaxed the medical indications for IVF, but it is not a complete放开.

It should be noted that "social egg freezing" or "non-medical sex selection" without medical indications are still not permitted under the policy.

1.3 Institutional Access: Secondary Hospitals Can Now Perform IVF

Previously, IVF had to be performed in tertiary Grade A hospitals or provincial reproductive centers. The 2026 new policy allows qualified secondary Grade A general hospitals to apply for performing artificial insemination by husband (AIH) and in vitro fertilization-embryo transfer (IVF-ET), subject to the following conditions:

• Annual outpatient volume ≥ 100,000 visits, obstetrics and gynecology beds ≥ 50;
• Possess an independent reproductive laboratory, with ≥ 2 full-time embryologists;
• Pass the acceptance check of the National Quality Control Center for Assisted Reproductive Technology;
• Establish a two-way referral mechanism with provincial reproductive centers.

This adjustment is mainly to shorten the medical journey for grassroots patients, but complex technologies like PGT and ICSI remain restricted to tertiary hospitals.

2. Why Were These Adjustments Made in 2026

Behind the policy changes are three direct driving factors.

First, the real pressure of continuously declining fertility rates. By 2024, the national total fertility rate had fallen below 1.0. Assisted reproduction is one of the most direct medical means to increase fertility rates. However, the high cost in the past (30,000-50,000 RMB per cycle) deterred many low- and middle-income families. The purpose of unified medical insurance payment is to lower the economic barrier.

Second, technological maturity is already in place. Over the past 10 years, the clinical pregnancy rate in domestic reproductive centers has increased from 35% to 55%-60%, and the embryo freezing and thawing survival rate has reached over 95%. The conditions for technology popularization are ripe, and policies need to keep pace with technological development.

Third, reducing regional imbalances in medical resources. Data from 2025 shows that 80% of the country's reproductive centers are concentrated in the eastern coastal areas and first-tier cities, with the rate of patients from central and western regions seeking cross-provincial medical treatment reaching as high as 45%. Allowing secondary hospitals to perform basic assisted reproduction is a concrete implementation of tiered diagnosis and treatment in the reproductive field.

3. Practitioner Observation: How Reproductive Center Doctors View These Changes

At the National Reproductive Medicine Annual Conference at the end of 2025, several directors of reproductive centers expressed the following consensus on the new policy:

• Regarding the expansion of medical insurance coverage: Including ovulation induction drugs in medical insurance is "the most tangible benefit" because these costs account for 30%-40% of the total cost per cycle, and patients often chose cheaper domestic drugs when paying out-of-pocket, affecting follicular development quality. With insurance coverage, doctors can choose more appropriate drug regimens based on the patient's ovarian response, rather than being limited by price.
• Regarding the relaxation of indications: Lowering the age for direct IVF from 40 to 38 aligns with the objective law of declining ovarian function with age. The rate of AMH decline in women aged 38 accelerates significantly. Starting the IVF process one year earlier could mean a difference of 10-15 percentage points in live birth rate.
• Regarding secondary hospital access: Some doctors worry about "increased cycle cancellation rates due to insufficient technical capacity at the grassroots level." However, the policy has set strict quality control thresholds – secondary hospitals newly starting assisted reproduction must have at least one year of operational experience in AIH (artificial insemination by husband) with a clinical pregnancy rate ≥ 15% before they can apply for IVF qualification.

4. 5 Easiest-to-Overlook Details

The policy document itself is not long, but the implementation details significantly impact patients. The following 5 points are easily overlooked:

1. Medical insurance reimbursement has a "waiting period": Patients undergoing their first IVF treatment must first pay out-of-pocket for all examinations (approximately 5,000-8,000 RMB). Reimbursement for cycle costs begins only after the medical record is established. Examination costs are not covered.
2. Embryo freezing costs are only reimbursed for the first year: The 2026 new policy only covers the first year of embryo freezing storage fees (approximately 1,200 RMB/year). Subsequent storage requires out-of-pocket payment. If multiple transfers are planned, the freezing cycle needs to be planned in advance.
3. PGT reimbursement has a "genetic disease directory": Reimbursement for PGT-M (monogenic diseases) is limited to the 156 severe genetic diseases published by the state. Diseases not on the list require out-of-pocket payment (approximately 20,000-30,000 RMB). Applying for reimbursement requires providing a genetic counseling report and genetic testing evidence.
4. Secondary hospitals cannot perform ICSI: If the male partner's sperm quality is extremely poor (requiring ICSI), even if the medical record is established at a secondary hospital, the patient must still be referred to a tertiary hospital for egg retrieval and fertilization. However, subsequent embryo transfer can be performed back at the secondary hospital.
5. Registered residence filing requirement: Some central and western provinces (e.g., Henan, Sichuan, Gansu) require patients to provide a "birth filing certificate" issued by the health commission of their registered residence; otherwise, medical insurance will not reimburse. Specific materials should be confirmed with the local medical insurance bureau in advance.

5. Under the 2026 Policy, What is the Specific IVF Process

After the policy adjustment, the standardized process is as follows:

Timeline Reference

Overall Cycle: From initial screening to confirmation of pregnancy, the fastest is 6-8 weeks (excluding PGT), and 10-12 weeks including PGT. If the first transfer fails, a frozen embryo transfer cycle only takes 4-6 weeks.

6. Special Situation Handling: Who Needs Extra Preparation

• AMH < 1.1 ng/mL: Indicates poor ovarian response (POR). The 2026 policy allows direct use of PPOS or mild stimulation protocols without first attempting conventional ovarian stimulation. However, the medical insurance reimbursement rate remains unchanged, and the risk of cycle cancellation is borne by the patient.
• Previous IVF failure ≥ 2 times: It is recommended to undergo ERA (Endometrial Receptivity Array) testing or hysteroscopy to rule out endometritis or displaced implantation window. ERA testing is currently not covered by medical insurance (approximately 3,000 RMB).
• One spouse is a carrier of Hepatitis B/Syphilis/HIV: Sperm washing or embryo screening must be performed in a designated infectious disease laboratory. The process differs from that for regular patients and must be communicated to the doctor in advance. Related testing costs are not reimbursed by medical insurance.
• Patients not holding local registered residence: Must provide a residence permit + proof of 6 consecutive months of local social security contributions to enjoy medical insurance reimbursement at the treatment location. If unable to provide these, they must apply for cross-provincial medical treatment filing in their registered residence.

7. Practitioner Observation: Real Feedback After Policy Implementation

In the first quarter of 2026, 17 secondary hospitals nationwide passed acceptance checks to perform IVF. Operational data shows:

• The average cost per cycle at secondary hospitals is 22% lower than at tertiary hospitals (mainly saved in bed fees and drug ratio), but the clinical pregnancy rate (45%-50%) is slightly lower than that of tertiary hospitals (55%-60%).
• After medical insurance reimbursement, the patient's out-of-pocket cost per cycle dropped from 30,000-50,000 RMB to 10,000-15,000 RMB (urban employees) or 20,000-25,000 RMB (urban and rural residents), and the cycle cancellation rate decreased by approximately 18%.
• The volume of PGT testing tripled after the new policy, mainly driven by recurrent miscarriage and advanced maternal age groups. However, about 30% of tested embryos were deemed non-transferable due to "mosaicism ≥ 20%". Most of these patients opted for another ovarian stimulation cycle after genetic counseling.

A notable trend is that more women aged 35-37 are choosing to enter the IVF process directly after the policy implementation, rather than first trying natural conception for 3-6 months. Reproductive doctors advise that even with insurance coverage, IVF should only be considered after 6 months of unsuccessful natural conception attempts to avoid overtreatment.